HUP9802634A3 - Use of benzimidazoles for the manufacture of pharmaceutical compositions for the treatment of leukemia - Google Patents

Use of benzimidazoles for the manufacture of pharmaceutical compositions for the treatment of leukemia

Info

Publication number
HUP9802634A3
HUP9802634A3 HU9802634A HUP9802634A HUP9802634A3 HU P9802634 A3 HUP9802634 A3 HU P9802634A3 HU 9802634 A HU9802634 A HU 9802634A HU P9802634 A HUP9802634 A HU P9802634A HU P9802634 A3 HUP9802634 A3 HU P9802634A3
Authority
HU
Hungary
Prior art keywords
benzimidazoles
leukemia
manufacture
treatment
pharmaceutical compositions
Prior art date
Application number
HU9802634A
Other languages
English (en)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of HUP9802634A2 publication Critical patent/HUP9802634A2/hu
Publication of HUP9802634A3 publication Critical patent/HUP9802634A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HU9802634A 1995-06-07 1996-05-22 Use of benzimidazoles for the manufacture of pharmaceutical compositions for the treatment of leukemia HUP9802634A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47381795A 1995-06-07 1995-06-07

Publications (2)

Publication Number Publication Date
HUP9802634A2 HUP9802634A2 (hu) 1999-03-29
HUP9802634A3 true HUP9802634A3 (en) 1999-05-28

Family

ID=23881113

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802634A HUP9802634A3 (en) 1995-06-07 1996-05-22 Use of benzimidazoles for the manufacture of pharmaceutical compositions for the treatment of leukemia

Country Status (17)

Country Link
EP (1) EP0831816A1 (hu)
JP (1) JPH11506732A (hu)
KR (1) KR19990022617A (hu)
CN (1) CN1186433A (hu)
AR (1) AR003137A1 (hu)
AU (1) AU717382B2 (hu)
BR (1) BR9608730A (hu)
CA (1) CA2223435A1 (hu)
CZ (1) CZ391197A3 (hu)
HU (1) HUP9802634A3 (hu)
IL (1) IL118424A0 (hu)
NO (1) NO975660L (hu)
PL (1) PL324026A1 (hu)
SK (1) SK168697A3 (hu)
TR (1) TR199701536T1 (hu)
WO (1) WO1996040122A1 (hu)
ZA (1) ZA964373B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL134354C (hu) * 1963-05-23
FR2155888A1 (en) * 1971-10-13 1973-05-25 Agot Aime Solid anthelmintic composn - for more economical treatment of ruminants
NZ305784A (en) * 1995-04-12 2001-03-30 Procter & Gamble Benzimidazole containing medicaments for treating cancers, tumors and viral infections

Also Published As

Publication number Publication date
ZA964373B (en) 1996-09-02
CZ391197A3 (cs) 1998-05-13
HUP9802634A2 (hu) 1999-03-29
EP0831816A1 (en) 1998-04-01
NO975660L (no) 1998-02-09
AR003137A1 (es) 1998-07-08
IL118424A0 (en) 1996-09-12
AU5802096A (en) 1996-12-30
NO975660D0 (no) 1997-12-05
JPH11506732A (ja) 1999-06-15
KR19990022617A (ko) 1999-03-25
TR199701536T1 (xx) 1998-02-21
PL324026A1 (en) 1998-05-11
CN1186433A (zh) 1998-07-01
CA2223435A1 (en) 1996-12-19
SK168697A3 (en) 1998-12-02
BR9608730A (pt) 1999-06-29
WO1996040122A1 (en) 1996-12-19
AU717382B2 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
HUP9801692A3 (en) Benzimidazole compounds, pharmaceutical compositions containing them and their use for producing pharmaceutical compositions
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
IL117957A0 (en) Pharmaceutical compositions for the treatment of impotence
HUP9801532A3 (en) Use of benzimidazole derivatives for producing pharmaceutical compositions for inhibiting the growth of cancers
HUP9601566A3 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
SG49956A1 (en) Pharmaceutical compositions containing irbesartan
HUP0102556A3 (en) Benzenesulfonamide-derivatives and their use as medicaments and process for the preparation of the compounds
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
ZA962916B (en) New arylglycineamide derivatives processes for the manufacture thereof and pharmaceutical compositions containing these compounds
HUP9802629A3 (en) Use of 1,3-bis(1,2,4-triazolyl)propan-2-ol derivatives for the manufacture of pharmaceutical compositions treating cancers
HUP0003982A3 (en) The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
HUP9903166A3 (en) Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
HUP9802634A3 (en) Use of benzimidazoles for the manufacture of pharmaceutical compositions for the treatment of leukemia
ZA952046B (en) Benzimidazoles pharmaceutical compositions containing these compounds and processes for preparing them
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
PL322526A1 (en) Azathiopyrin compositions for intracolic administration
IL117656A0 (en) Pharmaceutical compositions for the treatment of travellers diarrhea
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
HU9600455D0 (en) Use of quinoxalines combined with protease-inhibiting compounds for producing pharmaceutical compositions for treating hiv infections
GB9414966D0 (en) Pharmaceutical compositions for the nasal administration of antiviral agents
EP0577023A3 (en) Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
HUP9903684A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating depression
HUP9900924A3 (en) Substituted 1 betha-d-arabinofuranosylcytosine derivatives and use of the same for producing pharmaceutical compositions having antitumor activity
IL119225A (en) Pharmaceutical compositions for the treatment of asthma in mammals
IL117655A0 (en) Pharmaceutical compositions for the treatment of travellers diarrhea